Home › Employers › AstraZeneca Pharmaceuticals LP › Associate Director
Associate Director at AstraZeneca Pharmaceuticals LP: H-1B salaries
8 labor condition applications for the job title Associate Director at AstraZeneca Pharmaceuticals LP. Median offered base salary $152,542; middle half $148,368–$157,011.
Applications (LCAs)8
Median offered salary$152,542
Middle half of salaries$148,368–$157,011
10th–90th percentile$146,887–$161,780
By fiscal year
| Fiscal year | LCAs | Median salary |
|---|---|---|
| FY2023 | 3 | $150,000 |
| FY2024 | 4 | $152,386 |
| FY2025 | 1 | $155,085 |
Applications
| Base salary | Location | Submitted | Start date | Status |
|---|---|---|---|---|
| $155,085 Level IV | Gaithersburg, MD | Jun 30, 2025 | Dec 29, 2025 | Certified |
| $155,948 Level III | Waltham, MA | Sep 5, 2024 | Feb 28, 2025 | Certified |
| $147,000 Level II | Gaithersburg, MD | Jul 22, 2024 | Sep 22, 2024 | Certified |
| $165,465 Level IV | Waltham, MA | Apr 17, 2024 | Oct 1, 2024 | Certified |
| $148,824 Level II | Waltham, MA | Feb 29, 2024 | Aug 30, 2024 | Certified |
| $146,624 Level III | Waltham, MA | May 26, 2023 | Oct 1, 2023 | Certified |
| $160,200 Level III | Gaithersburg, MD | Apr 4, 2023 | Oct 1, 2023 | Certified |
| $150,000 E-3 · Level III | Gaithersburg, MD | Jan 18, 2023 | Jun 24, 2023 | Certified |
Associate Director at all employers →
Other jobs at AstraZeneca Pharmaceuticals LP
- Senior Scientist$125,840
- Statistical Programming Associate Director$162,540
- Scientist$102,298
- Director, Statistical Programming$185,389
- Associate Director, Systems Medicine$152,157
- Senior Statistician I$130,515
- Statistical Science Associate Director$173,640
- Senior Statistician$129,293
- Senior Statistician II$153,000
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).